Our New 10-Year Vision is Approved!

Alzheimer's Association

This message is sent to all Alzheimer's Association and Alzheimer's
Impact Movement board members, all Alzheimer's Association staff, and
volunteers and supporters of AIM and the Alzheimer's Association.

Today, we celebrate another important milestone in Alzheimer's
treatment. The U.S. Food and Drug Administration (FDA) granted
traditional approval of donanemab, sold under the brand name Kisunla,
for the treatment of people living with early symptomatic
Alzheimer's disease, which includes mild cognitive impairment
and the mild dementia stage of Alzheimer's disease, with
confirmed amyloid plaques. This is the third FDA approval granted for
an Alzheimer's treatment that changes the underlying course of
the disease. Learn more here.

[link removed]

This is real progress. Today's action gives people more options
and greater opportunity to have more time.

We are making an impact both globally and in communities. Whether you
volunteer with us, donate or advocate for families facing dementia,
our progress is only possible because of you.

Barbara Eades, of Chattanooga, Tennessee, was diagnosed with mild
cognitive impairment (MCI) in 2018. She shares, "Today's
decision by the FDA is good news for those of us living with early
Alzheimer's. I was fortunate to participate in the clinical
trial and receive this treatment. It has provided me an opportunity to
live my life fully, for more time. I'm able to keep doing what
I'm passionate about: sing, remain active in my church and spend
time with my friends and family."

Because of Barbara and the millions of people facing this devastating
disease, the Alzheimer's Association is leading the way with a
comprehensive approach to helping those who need us most. The
Alzheimer's Association accelerates research, supports people
and families, advances public policy, and engages volunteers and
communities.

We have more reasons than ever to believe we will achieve a world
without Alzheimer's and all other dementia. Our work is not
done. We won't rest until everyone living with Alzheimer's
- at any stage - can get the diagnosis, treatment, care
and support they need and deserve.

Thank you for all you do to move our mission forward. You can always
find additional information at alz.org or at our 24/7 Helpline
(800.272.3900).

Joanne Pike, DrPH

President & CEO

Alzheimer's Association Home Office, 225
N. Michigan Ave., Fl. 17, Chicago, IL 60601

© 2024 Alzheimer's
Association. All rights reserved.
800.272.3900 | alz.org

[link removed]

® | Donate

[link removed]

 
Having trouble reading this email?

View it in your browser

[link removed]

 

View your email preferences or
unsubscribe.
[link removed]



To unsubscribe from all future email, paste the following URL into your browser:
[link removed]